|Videos|September 7, 2016

How Do EDCs Affect Viral Loads in Infected Mosquitoes?

Justin R. Anderson, PhD, associate professor of biology at Radford University, discusses how endocrine disrupting chemicals (EDCs) affect the amount of a virus in infected mosquitoes.

Justin R. Anderson, PhD, associate professor of biology at Radford University, discusses how endocrine disrupting chemicals (EDCs) affect viral loads in infected mosquitoes.

Interview Transcript (slightly modified for readability)

“In our study, we tested endocrine disrupting chemicals like [Bisphenol A] BPA against La Crosse virus replication in a mammalian cell to get an initial finding on what we can expect in an infected mosquito. We found that, as the course of the infection went on, the amount of virus that was produced increased after exposure to EDCs compared to cells that did not have endocrine disrupters. So, we don’t know [the] mechanism [that’s] going on inside those cells, but we see more virus being produced in cells that are infected after they’ve been exposed to endocrine disrupting chemicals.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.